期刊文献+

首次缓解后使用小剂量IL-2免疫治疗不能改善≥60岁老年急性髓性白血病患者预后

Low-Dose lnterleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older with Acute Myeloid Leukemia in First Complete Remission//
下载PDF
导出
摘要 1文献来源 Low-dose Interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. [J]. J Clin Oncol, 2008,12(26):4934-4939.
出处 《循证医学》 CSCD 2009年第5期274-276,共3页 The Journal of Evidence-Based Medicine
关键词 急性髓性白血病 老年患者 白介素2 acute myeloid leukemia elderly patients Interleukin-2 (IL-2)
  • 相关文献

参考文献3

  • 1Caligiuri MA, Murray C, Robertson M J, et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2 [J]. J Clin Invest, 1993,91 ( 1 ) : 123-132.
  • 2Stone RM, DeAngelo D J, Janosova A, et al. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission [J]. Am J Hematol, 2008, 83(10):771-777.
  • 3Miyake H, Kurahashi T, Takenaka A, et al. Clinical outcome of combined immunotherapy with interferon-a and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma [J]. Urol Oncol, 2008, Sep 23, Epub ahead of print.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部